Clinical Trials Browser

Interventional × Ondansetron × 90 days × Clear all

NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections